Omeros(US:OMER) Businesswire·2026-03-21 07:23Company Overview - Omeros Corporation is an innovative, commercial-stage biotechnology company focused on discovering and developing first-in-class therapeutics for large-market and orphan indications, particularly in complement-mediated diseases, cancers, and addictive disorders [2] - The company's lead product, YARTEMLEA® (narsoplimab-wuug), is FDA-approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged two years and older [2] - Omeros is also advancing its pipeline, including OMS1029, a long-acting MASP-2 inhibitor that has completed Phase 1 clinical trials [2] Recent Developments - Omeros will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, focusing on advances in TA-TMA treatment [1] - The session will be co-chaired by notable experts and will feature presentations from leading professionals in the field [1] - Omeros has recently completed its first commercial shipments of YARTEMLEA to distributors, with orders from transplant centers beginning immediately [7] Strategic Partnerships - Novo Nordisk has acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other indications, along with associated intellectual property [3] - Omeros' pipeline also includes OMS527, a phosphodiesterase 7 inhibitor for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse [3]